About the 5th Gene Therapy for Ophthalmic Disorders Summit
This extensive three-day event will tackle obstacles spanning preclinical and clinical development. From engineering AAVs and innovating vectors for enhanced delivery and transduction to specific target cells, to confirming suitable clinical endpoints that demonstrate efficacy, all facets will be covered.
Drawing in teams from R&D, preclinical, and clinical development sectors of prominent biotech and pharmaceutical companies, this gathering offers a chance to gain insights into successful strategies shared by those with first-hand experience in developing ocular gene therapies.
What's New for 2024?
Gain insights into cutting-edge RNA-based therapeutics and gene editing therapies aimed at enhancing precision and efficacy. Learn how ASOs may tackle delivery challenges with Astherna and discover how the engineered ribonucleoprotein (eRNP) CRISPR gene editor platform from Spotlight Therapeutics enables safe and efficient gene modification.
Uncover new data on optimizing capsids for suprachoroidal injection to address delivery hurdles with Frontera Therapeutics. Explore advancements in gene therapy vectors using the scAAVengr platform and machine learning to optimize vector performance with Avista Therapeutics.
Harness new technologies at the 2024 summit, including innovative synthetic AAV constructs and for non-viral gene editing showcased by Visgenx Inc., and dive into cutting-edge approaches to patient testing and clinical readiness in optogenetics for ocular disorders with Ray Therapeutics, Inc.
Discover the latest clinical updates from Nanoscope Therapeutics, Ocugen and the BGT Foundation. Explore case studies on achieving clinical trial readiness, with insights on navigating phases 2 and 3 of trials with Adverum and Novartis ensuring safety, efficacy, and vector optimization.
Who Will You Meet?
Join teams across R&D, preclinical and clinical development from the leading biotech and pharma companies in the space at the only industry-focused event tackling specific ocular gene therapy development and delivery challenges from preclinical through to clinical drug development.
Testimonials:
“Small groups and great personal interactions. It was wonderful to have the opportunity to ask and hear many questions from the community."
A Gene Therapy for Ophthalmic Disorders 2023 attendee, Kriya Therapeutics
“The conference was an exciting and impressive gathering of minds with a collective goal to push gene therapy forward. An amazing opportunity to listen in on the past and the future of the industry."
A Gene Therapy for Ophthalmic Disorders 2023 attendee, iuvo BioScience
“Diverse mix of attendees and presenters creating comprehensive coverage and fantastic expertise, small enough to facilitate audience participation, informal discussions, and excellent networking."
A Gene Therapy for Ophthalmic Disorders 2023 attendee, Duke University